|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DeSantis C, Siegel R, Bandi P and Jemal A:
Breast cancer statistics, 2011. CA Cancer J Clin. 61:409–418. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McGuire A, Brown JA, Malone C, McLaughlin
R and Kerin MJ: Effects of age on the detection and management of
breast cancer. Cancers (Basel). 7:908–929. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Veronesi U, Boyle P, Goldhirsch A,
Orecchia R and Viale G: Breast cancer. Lancet. 365:1727–1741. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang BN, Cao XC, Chen JY, Chen J, Fu L,
Hu XC, Jiang ZF, Li HY, Liao N, Liu DG, et al: Guidelines on the
diagnosis and treatment of breast cancer (2011 edition). Gland
Surg. 1:39–61. 2011.
|
|
6
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nohata N, Hanazawa T, Enokida H and Seki
N: microRNA-1/133a and microRNA-206/133b clusters: Dysregulation
and functional roles in human cancers. Oncotarget. 3:9–21. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lerebours F, Cizeron-Clairac G, Susini A,
Vacher S, Mouret-Fourme E, Belichard C, Brain E, Alberini JL,
Spyratos F, Lidereau R and Bieche I: miRNA expression profiling of
inflammatory breast cancer identifies a 5-miRNA signature
predictive of breast tumor aggressiveness. Int J Cancer.
133:1614–1623. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu
H, Liu MF and Wang ED: MicroRNA-155 functions as an OncomiR in
breast cancer by targeting the suppressor of cytokine signaling 1
gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J
and Zhang HT: MiR-142-3p represses TGF-β-induced growth inhibition
through repression of TGFβR1 in non-small cell lung cancer. FASEB
J. 28:2696–2704. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shen WW, Zeng Z, Zhu WX and Fu GH:
MiR-142-3p functions as a tumor suppressor by targeting CD133,
ABCG2, and Lgr5 in colon cancer cells. J Mol Med (Berl).
91:989–1000. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chai S, Tong M, Ng KY, Kwan PS, Chan YP,
Fung TM, Lee TK, Wong N, Xie D, Yuan YF, et al: Regulatory role of
miR-142-3p on the functional hepatic cancer stem cell marker CD133.
Oncotarget. 5:5725–5735. 2001.
|
|
14
|
Isobe T, Hisamori S, Hogan DJ, Zabala M,
Hendrickson DG, Dalerba P, Cai S, Scheeren F, Kuo AH, Sikandar SS,
et al: miR-142 regulates the tumorigenicity of human breast cancer
stem cells through the canonical WNT signaling pathway. eLife.
3:e019772014. View Article : Google Scholar :
|
|
15
|
Wang B, Li J, Sun M, Sun L and Zhang X:
miRNA expression in breast cancer varies with lymph node metastasis
and other clinicopathologic features. IUBMB Life. 66:371–377. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xu R, Bi C, Song J, Wang L, Ge C, Liu X
and Zhang M: Upregulation of miR-142-5p in atherosclerotic plaques
and regulation of oxidized low-density lipoprotein-induced
apoptosis in macrophages. Mol Med Rep. 11:3229–3234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su YH, Zhou Z, Yang KP, Wang XG, Zhu Y and
Fa XE: MIR-142-5p and miR-9 may be involved in squamous lung cancer
by regulating cell cycle related genes. Eur Rev Med Pharmacol Sci.
17:3213–3220. 2013.PubMed/NCBI
|
|
18
|
Zhu J, Zhang Y, Zhang W, Zhang W, Fan L,
Wang L, Liu Y, Liu S, Guo Y, Wang Y, et al: MicroRNA-142-5p
contributes to Hashimoto's thyroiditis by targeting CLDN1. J Transl
Med. 14:1662016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K,
Ren W, Zhang X, Shu P and Zhang D: miR-142-5p promotes development
of colorectal cancer through targeting SDHB and facilitating
generation of aerobic glycolysis. Biomed Pharmacother.
92:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Liu M, Yang H, Wang J, Liu H and
Li X, Li J, Xu J and Li X: PIK3CA mutations are a predictor of
docetaxel plus epirubicin neoadjuvant chemotherapy clinical
efficacy in breast cancer. Neoplasma. 61:461–467. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li J, Yen C, Liaw D, Podsypanina K, Bose
S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al:
PTEN, a putative protein tyrosine phosphatase gene mutated in human
brain, breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu L, Liu S, Duan Q, Chen L, Wu T, Qian
H, Yang S, Xin D, He Z and Guo Y: MicroRNA-142-5p promoted cell
growth and migration in renal cell carcinoma by targeting BTG3. Am
J Transl Res. 9:2394–2402. 2017.PubMed/NCBI
|
|
25
|
Stemke-Hale K, Gonzalez-Angulo AM, Lluch
A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, et
al: An integrative genomic and proteomic analysis of PIK3CA, PTEN,
and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nagata Y, Lan KH, Zhou X, Tan M, Esteva
FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al: PTEN
activation contributes to tumor inhibition by trastuzumab, and loss
of PTEN predicts trastuzumab resistance in patients. Cancer Cell.
6:117–127. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Board RE, Thelwell NJ, Ravetto PF, Little
S, Ranson M, Dive C, Hughes A and Whitcombe D: Multiplexed assays
for detection of mutations in PIK3CA. Clin Chem. 54:757–760. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Milella M, Falcone I, Conciatori F, Incani
Cesta U, Del Curatolo A, Inzerilli N, Nuzzo CM, Vaccaro V, Vari S,
Cognetti F and Ciuffreda L: PTEN: Multiple functions in human
malignant tumors. Front Oncol. 5:242015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Baselga J: Targeting the
phosphoinositide-3 (PI3) kinase pathway in breast cancer.
Oncologist. 16 Suppl 1:S12–S19. 2011. View Article : Google Scholar
|
|
30
|
Carracedo A and Pandolfi PP: The PTEN-PI3K
pathway: Of feedbacks and cross-talks. Oncogene. 27:5527–5541.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bai X, Zhou Y, Chen P, Yang M and Xu J:
MicroRNA-142-5p induces cancer stem cell-like properties of
cutaneous squamous cell carcinoma via inhibiting PTEN. J Cell
Biochem. 119:2179–2188. 2018. View Article : Google Scholar : PubMed/NCBI
|
